• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Celgene Corporation

Celgene Corporation

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Celgene Announces Positive Results from RADIANCE, the Second Pivotal Phase III Trial of Oral Ozanimod in Patients with Relapsing Multiple Sclerosis

    Celgene Announces Positive Results from RADIANCE, the Second Pivotal Phase III Trial of Oral Ozanimod in Patients with Relapsing Multiple Sclerosis

  2. Broad Range of Clinical Data Evaluating Celgene Therapies to Be Presented at American Society of Clinical Oncology (ASCO)

    Broad Range of Clinical Data Evaluating Celgene Therapies to Be Presented at American Society of Clinical Oncology (ASCO)

  3. Juno Therapeutics to Present Key Clinical Data Updates on JCAR017 and JCAR014 at the 2017 American Society of Clinical Oncology Annual Meeting

    Juno Therapeutics to Present Key Clinical Data Updates on JCAR017 and JCAR014 at the 2017 American Society of Clinical Oncology Annual Meeting

  4. Celgene reports positive results in trial of multiple sclerosis treatment

    Celgene reports positive results in trial of multiple sclerosis treatment

  5. MetaStat Elevates Jerome B. Zeldis, M.D., Ph.D. to Chairman of the Board and Appoints Douglas A. Hamilton, MetaStat’s President and CEO to its Board of Directors

    MetaStat Elevates Jerome B. Zeldis, M.D., Ph.D. to Chairman of the Board and Appoints Douglas A. Hamilton, MetaStat’s President and CEO to its Board of Directors

  6. Blood Cancer Drugs Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2023 - Research and Markets

    Blood Cancer Drugs Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2023 - Research and Markets

  7. Share Repurchase: Potential Signal of Undervaluation and Outperformance

    Celgene's CELG prized drug Revlimid was approved for multiple myeloma in June, and third-quarter results gave us our first look at sales for its use in treating a second form of blood cancer. While Revlimid's multiple myeloma launch was strong and did not appear to cannibalize legacy drug ...

  8. Will the Election Affect Earnings?

    If Americans sweep Democrats into office, these healthcare proposals could get a shot in the arm. Here’s how they would have an impact on earnings.

  9. Our Outlook for the Credit Markets

    Widening investment-grade credit spreads and rising interest rates lead to losses.

  10. Credit Market Outlook: Bonds Priced for the Benign

    Corporate credit spreads are fairly valued--albeit at the tight end of the range that we view as fairly valued.

123

©2017 Morningstar Advisor. All right reserved.